Pliant Therapeutics, Inc.

MUN:9PT Stock Report

Market Cap: €1.5b

Pliant Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bernard Coulie

Chief executive officer

US$5.2m

Total compensation

CEO salary percentage10.7%
CEO tenure7.2yrs
CEO ownership0.9%
Management average tenure7.1yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bernard Coulie's remuneration changed compared to Pliant Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$123m

Sep 30 2022n/an/a

-US$113m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$103m

Dec 31 2021US$5mUS$556k

-US$97m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$499k

-US$42m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$19m

Mar 31 2020n/an/a

US$20m

Dec 31 2019US$2mUS$428k

-US$7m

Compensation vs Market: Bernard's total compensation ($USD5.19M) is above average for companies of similar size in the German market ($USD1.56M).

Compensation vs Earnings: Bernard's compensation has increased whilst the company is unprofitable.

CEO

Bernard Coulie (56 yo)

7.2yrs

Tenure

US$5,190,781

Compensation

Dr. Bernard Coulie, Ph. D, M. D., M. B.A., serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairman since November 2022. He serves as President a...

Leadership Team

NamePositionTenureCompensationOwnership
Bernard Coulie
Presidentno dataUS$5.19m0.91%
€ 13.8m
Keith Cummings
Chief Financial Officer4.3yrsUS$1.88m0.16%
€ 2.4m
Mike Ouimette
General Counsel & Corporate Secretary2.5yrsUS$805.04k0.020%
€ 302.3k
Johannes Hull
Chief Business Officer7.1yrsUS$1.65m0.30%
€ 4.6m
Éric Lefebvre
Chief Medical Officer4.9yrsUS$1.97mno data
Rik Derynck
Scientific Founder & Member of Scientific Advisory Board8.3yrsno datano data
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Board8.3yrsno datano data
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Board8.3yrsno datano data
Hal Chapman
Scientific Founder & Member of Scientific Advisory Board8.3yrsno datano data
Craig Muir
Interim Chief Technology Officerno datano datano data
Christopher Keenan
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Lily Cheung
Chief Human Resources Officerless than a yearno datano data

7.1yrs

Average Tenure

49yo

Average Age

Experienced Management: 9PT's management team is seasoned and experienced (7.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bernard Coulie
President7.2yrsUS$5.19m0.91%
€ 13.8m
Rik Derynck
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Hal Chapman
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Gayle Crowell
Independent Director3.3yrsUS$287.91k0%
€ 0
Brian Metcalf
Member of Scientific Advisory Boardno datano datano data
Suzanne Bruhn
Independent Director6.8yrsUS$288.29k0.059%
€ 899.3k
John Curnutte
Independent Director5.7yrsUS$286.41k0.049%
€ 750.6k
Hoyoung Huh
Independent Chairman5.3yrsUS$308.41k0%
€ 0
Smital Shah
Independent Director4.1yrsUS$288.41k0%
€ 0
Bill Greenlee
Member of Scientific Advisory Boardno datano datano data

5.5yrs

Average Tenure

59yo

Average Age

Experienced Board: 9PT's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/30 17:29
End of Day Share Price 2023/01/31 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pliant Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward NashCanaccord Genuity
Pete StavropoulosCantor Fitzgerald & Co.
David LebowitzCitigroup Inc